174 related articles for article (PubMed ID: 14672741)
1. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.
Laïos I; Journe F; Laurent G; Nonclercq D; Toillon RA; Seo HS; Leclercq G
J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):207-21. PubMed ID: 14672741
[TBL] [Abstract][Full Text] [Related]
2. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
3. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
El Khissiin A; Journé F; Laïos I; Seo HS; Leclercq G
Steroids; 2000 Dec; 65(12):903-13. PubMed ID: 11077089
[TBL] [Abstract][Full Text] [Related]
4. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells.
Laïos I; Journé F; Nonclercq D; Vidal DS; Toillon RA; Laurent G; Leclercq G
J Steroid Biochem Mol Biol; 2005 Mar; 94(4):347-59. PubMed ID: 15857754
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
7. Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.
Journé F; Body JJ; Leclercq G; Nonclercq D; Laurent G
Breast Cancer Res Treat; 2004 Jul; 86(1):39-53. PubMed ID: 15218360
[TBL] [Abstract][Full Text] [Related]
8. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
9. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
10. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
11. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
12. The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
Memminger M; Keller M; Lopuch M; Pop N; Bernhardt G; von Angerer E; Buschauer A
PLoS One; 2012; 7(12):e51032. PubMed ID: 23236424
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells.
Borrás M; Laios I; el Khissiin A; Seo HS; Lempereur F; Legros N; Leclercq G
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):203-13. PubMed ID: 8645630
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
15. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
18. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment.
Leclercq G; Legros N; Piccart MJ
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):545-52. PubMed ID: 1562525
[TBL] [Abstract][Full Text] [Related]
20. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
Brockdorff BL; Heiberg I; Lykkesfeldt AE
Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
